Oncology Pipeline & Trials
Oncology Pipeline Snapshot as of January 28, 2020
- Discovery Projects
-
14Phase 1
-
10Phase 2
-
11Phase 3
-
5Registration
- Total40
|
Compound Name |
Indication |
Phase |
Submission Type |
Compound Type |
|---|---|---|---|---|
|
Xtandi (enzalutamide)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
Androgen receptor inhibitor |
Metastatic Hormone Sensitive Prostate Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
|
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma Mechanism of Action:
Human Granulocyte Colony Stimulating Factor |
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.) | Registration | Biosimilar | Biosimilar |
|
PF-05280586, a potential biosimilar to Rituxan® /MabThera® (rituximab)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma Mechanism of Action:
CD20 Antigen Antagonist |
Follicular Lymphoma (Biosimilar) (E.U.) | Registration | Biosimilar | Biosimilar |
|
Daurismo (glasdegib)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
SMO (smoothened) antagonist |
Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) | Registration | New Molecular Entity | Small Molecule |
|
Braftovi (encorafinib) + Erbitux®(cetuximab)
Therapeutic Area:
Oncology Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
BRAF kinased inhibitor and EGFR inhibitor |
2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (PRIORITY REVIEW - U.S., E.U.) Project advanced |
Registration | Product Enhancement | Small Molecule |
|
Xtandi (enzalutamide)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
Androgen receptor inhibitor |
Non-metastatic High Risk Hormone Sensitive Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
Talzenna (talazoparib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
PARP inhibitor |
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
PF-06801591 + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
WRDM Mechanism of Action:
Anti-PD-1 |
Non-Muscle-Invasive Bladder cancer (Biologic) Project advanced |
Phase 3 | New Molecular Entity | Biologic |
|
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
ALK Inhibitor |
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) | Phase 3 | Product Enhancement | Small Molecule |
|
Ibrance (palbociclib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
CDK 4,6 Kinase Inhibitor |
High Risk Early Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
Ibrance (palbociclib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
CDK 4,6 Kinase Inhibitor |
Early Breast Cancer in Adjuvant Setting | Phase 3 | Product Enhancement | Small Molecule |
|
Ibrance (palbociclib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
CDK 4,6 Kinase Inhibitor |
ER+/HER2+ Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
|
Daurismo (glasdegib)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
SMO (smoothened) antagonist |
Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Small Molecule |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma Mechanism of Action:
Anti PD-L1 |
1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma Mechanism of Action:
Anti PD-L1 |
1st Line Urothelial Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Bavencio (avelumab)
Therapeutic Area:
Oncology Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma Mechanism of Action:
Anti PD-L1 |
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) | Phase 3 | Product Enhancement | Biologic |
|
Talzenna (talazoparib)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
PARP inhibitor |
2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
|
Talzenna (talazoparib)
Therapeutic Area:
Oncology Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma Mechanism of Action:
PARP inhibitor |
Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer | Phase 2 | Product Enhancement | Small Molecule |
